Related Experiment Video
Updated: Jun 18, 2025

Establishment of a Clinic-based Biorepository
Published on: May 29, 2017
Skin cancer: What happens in the laboratory?
Simon P Clark1, Olivia MM Clark2, Denis H Moir3
1MBChB, FRCPA, Dermatopathologist, Douglass Hanly Moir Pathology @ Macquarie Park, Sydney, NSW; Senior Lecturer, Faculty of Medicine, The University of Queensland, Brisbane, Qld; Visiting Professor, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Background:
Skin cancer specimen handling in Australian histopathology laboratories, while largely standardised, exhibits significant variations that affect clinical decision-making and patient outcomes.
Objective:
This article provides clinicians with an understanding of histopathological processes to enhance diagnostic precision, inform surgical margin evaluations and refine management approaches.
Discussion:
Understanding specimen handling and protocols is vital for accurate interpretation of pathology reports and management of skin cancers. Variations in sampling, examination and sectioning can affect pathological diagnosis and margin assessment. Clinician insights into laboratory processes are crucial for best practice. Retention of specimens and reports allows for further evaluation if clinical circumstances evolve or additional investigations are required.

![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)